trending Market Intelligence /marketintelligence/en/news-insights/trending/linHFqeP7hbkCyroDDFPsw2 content esgSubNav
In This List

Astellas Pharma to transfer pain drug rights to Grünenthal

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Astellas Pharma to transfer pain drug rights to Grünenthal

Astellas Pharma Inc. said Astellas Pharma Europe Ltd. signed a definitive agreement with Grünenthal to transfer the rights for Astella's Qutenza, a pain relief patch, in Europe, the Middle East and Africa to Grünenthal.

The deal is expected to be completed in 2018.

Tokyo-based Astella's Qutenza is used for the treatment of peripheral neuropathic pain in adults.